Algernon to Launch First U.S. Brain-Dedicated PET Clinic in Florida as It Builds National Network

Algernon Pharmaceuticals ( (TSE:AGN) ) has provided an update.

Algernon Health will open its first brain-dedicated PET scanning clinic at the HCA Florida University Medical Office Building in Davie, on the campus of HCA Florida University Hospital, under a five-year lease with an option to renew. The clinic, the first of its kind in the U.S., will focus on brain PET scans to aid in detecting Alzheimer’s disease, other dementias, epilepsy, neuro-oncology conditions and movement disorders such as Parkinson’s disease, with beta-amyloid scans for patients 65 and older reimbursed by Medicare, Medicaid and private insurers.

The site will feature the FDA-cleared CareMiBrain system, a standalone PET scanner that delivers high-quality images with about 25% less radiation than traditional PET/CT systems, addressing a capacity gap as existing PET/CT machines are heavily utilized for oncology and cardiac imaging. Algernon plans to partner with neurologists, geriatricians and primary care physicians for referrals, market directly to the 50-plus population for earlier Alzheimer’s detection, and scale to multiple U.S. locations supported by a CAD $4 million non-dilutive equipment financing deal for up to 10 CareMiBrain units.

Located in Broward County, the flagship Davie clinic will draw on a catchment area of more than 6.4 million people within 60 miles, including 2.5 million aged 50 and over, aligning its services with a large at-risk demographic. The move positions Algernon to capitalize on rising demand for beta-amyloid brain scans driven by new monoclonal antibody Alzheimer’s treatments, which require a positive scan for access and have created a significant new market for brain-specific PET imaging and related therapies.

The most recent analyst rating on (TSE:AGN) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Algernon Pharmaceuticals stock, see the TSE:AGN Stock Forecast page.

Spark’s Take on AGN Stock

According to Spark, TipRanks’ AI Analyst, AGN is a Neutral.

The score is driven primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by improving loss/burn trends and a debt-free balance sheet. Technical indicators add further pressure due to clear bearish trend and weak momentum, while valuation is limited by negative earnings and no dividend support.

To see Spark’s full report on AGN stock, click here.

More about Algernon Pharmaceuticals

Algernon Health Inc. is a healthcare company focused on neuroimaging services, operating through its U.S. subsidiary Algernon USA LLC. The company is targeting the growing market for brain-dedicated PET diagnostics, particularly for Alzheimer’s disease, dementia and other neurological disorders, by developing a network of specialized clinics across the United States.

Average Trading Volume: 95,346

Technical Sentiment Signal: Sell

Current Market Cap: C$1.86M

Find detailed analytics on AGN stock on TipRanks’ Stock Analysis page.